Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/16569
Title: A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-beta and vascular endothelial growth factor signalling
Authors: Liu, Y
Wang, Z
Wang, J
Lam, W
Kwong, S
Li, F
Friedman, SL
Zhou, S
Ren, Q
Xu, Z
Wang, X
Ji, L
Tang, S
Zhang, H
Lui, EL
Ye, T 
Keywords: Angiogenesis
Hepatic stellate cells
Largazole
Liver fibrosis
TGF
VEGF
Issue Date: 2013
Publisher: Wiley-Blackwell
Source: Liver international, 2013, v. 33, no. 4, p. 504-515 How to cite?
Journal: Liver International 
Abstract: Background & Aims Largazole is a novel histone deacetylase (HDAC) inhibitor. This study investigated the effects of largazole against liver fibrosis. Methods The in vitro effects of largazole were examined using hepatic stellate cells (HSCs). In vivo effects of largazole were studied using a mouse liver fibrotic model induced by CCl4. Results Largazole augmented acetylation of histone H3 (H3) and histone H4 (H4) in HSCs. It directly inhibited the activation of HSCs owing to HDAC inhibitory activity as the antifibrotic effect of largazole was significantly decreased in cells with HDAC1, HDAC2 and HDAC3 knockdown. Largazole also induced apoptosis of HSCs. Largazole not only inhibited the expression of TGFR2, but also reduced phosphorylation of Smad2 and Akt induced by TGF-1. Largazole also inhibited the expression of vascular endothelial growth factor (VEGF) and its receptor. VEGF-induced proliferation of HSCs and activation of Akt and p38MAPK were also suppressed by largazole. In vivo, largazole reduced the expression of collagen I, -smooth muscle actin and tissue inhibitor of metalloproteinase-1 in CCl4induced fibrosis, and these antifibrotic effects were associated with increased acetylation of H3 and H4. Largazole also induced HSCs to undergo apoptosis in vivo, which was correlated with downregulation of bcl-2 and bcl-xL. Furthermore, largazole inhibited angiogenesis in vivo as evidenced by reduced expression of CD34, VEGF and VEGFR. In addition to its antifibrotic activity, the drug reduced inflammatory activity in CCl4-induced liver fibrosis. Conclusions Our findings revealed a novel role of largazole in the treatment of liver fibrosis. Through multiple mechanisms, largazole could be a potentially effective antifibrotic agent.
URI: http://hdl.handle.net/10397/16569
ISSN: 1478-3223
DOI: 10.1111/liv.12034
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

35
Last Week
0
Last month
Citations as of Feb 25, 2017

WEB OF SCIENCETM
Citations

30
Last Week
0
Last month
0
Citations as of Aug 12, 2017

Page view(s)

35
Last Week
2
Last month
Checked on Aug 13, 2017

Google ScholarTM

Check

Altmetric



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.